Are glucocorticoids still the mainstay of treatment in polymyalgia rheumatica and giant cell arteritis?
Are glucocorticoids still the mainstay of treatment of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA), or should we consider glucocorticoid-sparing agents earlier than before?